JDRF-Funded Islet Encapsulation Program Reaches Historic Milestone

[Northerner]

JDRF, the leading research and advocacy organization funding type 1 diabetes (T1D) research, announced today that JDRF-funded partner, ViaCyte, Inc., a leading regenerative medicine company, has for the first time ever implanted a person with type 1 diabetes (T1D) with an experimental encapsulated cell therapy product candidate, called VC-01TM, which is being developed for the treatment of T1D. This individual, and others to follow, is participating in a trial to evaluate the safety and efficacy of the VC-01 product candidate, a potential replacement source of insulin-producing cells.

http://jdrf.org/press-releases/jdrf-funded-islet-encapsulation-program-reaches-historic-milestone/